EIM
ECYT

Essex Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Essex Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-204,153
Closed -$4.86M – 386
2014
Q1 		$4.86M Buy
204,153
+63,729
+45% +$924K 0.71% 31
2013
Q4 		$1.5M Buy
140,424
+122,807
+697% +$1.36M 0.21% 145
2013
Q3 		$235K Buy
+17,617
New +$279K 0.04% 325

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Essex Investment Management's ECYT Position: Q2 2014 in Review

Essex Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 204,153 shares — an estimated $4.86M sold.

Essex Investment Management first reported a position in ECYT in Q3 2013 and held it in 3 quarters. The position peaked at $4.86M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

  • Essex Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Essex Investment Management sold 204,153 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $4.86M.
  • Essex Investment Management first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 3 quarters.
  • Essex Investment Management's Endocyte, Inc. Common Stock position peaked at $4.86M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on Essex Investment Management's 13F filing for Q2 2014, filed 23 Jul 2014.